Tango Therapeutics announced that Dr. Barbara Weber will retire as chief executive officer effective January 8 2026 and will become Executive Chair for the remainder of 2026, before moving to a non‑executive chair role in 2027. Dr. Malte Peters, a long‑time board member and former chief development officer at MorphoSys, will take on the roles of President and CEO, bringing more than a decade of late‑stage clinical development experience to the company.
Dr. Weber, who founded Tango in 2018, has overseen the company’s growth from a small research startup into a publicly traded biopharma focused on PRMT5 inhibition. Dr. Peters’ background at MorphoSys, where he led multiple oncology programs through pivotal trials, positions him to accelerate Tango’s pipeline and navigate the regulatory and commercial challenges ahead. The transition is framed as a strategic hand‑off that preserves continuity while injecting fresh executive expertise to drive the next phase of product development.
The leadership change is closely tied to Tango’s flagship candidate, vopimetostat (TNG462), a PRMT5 inhibitor for MTAP‑deleted cancers. The company will launch a pivotal second‑line pancreatic cancer trial in 2026, comparing vopimetostat to standard chemotherapy. Combination studies with Revolution Medicines’ RAS(ON) inhibitors are also underway, with data expected later in 2026. Other pipeline assets, including the brain‑penetrant PRMT5 inhibitor TNG456 and the CoREST inhibitor TNG260, are slated for early‑stage data releases in 2026.
Financially, Tango remains in a cash‑rich position, reporting $217 million in cash as of March 31 2025, which extends its runway into the first quarter of 2027. The company has experienced significant operating losses and negative margins, but maintains robust liquidity ratios and a conservative debt‑to‑equity profile. The leadership transition is expected to support disciplined capital allocation while the company continues to invest in its clinical programs.
"It has been an extraordinary privilege to build and lead Tango from its inception," said Dr. Weber. "With vopimetostat now advancing into its first registrational trial and actively enrolling potentially transformative combination studies, this is the right moment for Malte’s leadership expertise and strategic vision to propel Tango into the next phase of growth.” Dr. Peters added, "I look forward to working with Barbara and the board to build on this strong foundation and pursue our shared vision for the future.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.